KR20160090662A

KR20160090662A - Composition for prevention or treatment of retinal diseases comprising small black soybean extract

Info

Publication number: KR20160090662A
Application number: KR1020150010743A
Authority: KR
Inventors: 정상훈; 강석우; 김경아
Original assignee: 한국과학기술연구원
Priority date: 2015-01-22
Filing date: 2015-01-22
Publication date: 2016-08-01
Also published as: CN105816508A

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating retinal diseases comprising a Rhynchosia nulubilis extract and a food composition for preventing or alleviating retinal diseases comprising a Rhynchosia nulubilis extract.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a composition for preventing or treating retinopathy,

Disclosed herein is a pharmaceutical composition for preventing or treating retinal disease, including a dry eye bean extract, and a food composition for preventing or ameliorating a retinal disease, including a big-eyed bean extract.

Retinitis pigmentosa (RP) is a progressive retinal degenerative disease caused by functional impairment of photoreceptors and retinal pigment epithelium distributed in the retina. Photoreceptors are light-sensitive sensory cells present in the retina, turning light into a nerve stimulus. Photoreceptors in the vertebrate retina have conical cells (cone), a photoreceptor that acts when light is high, and rod cells, which act as light receptors in dim light. In RP, damage occurs in two cells. Bar cells are used to distinguish between light and dark, conical cells distinguish colors and transmit visual information transmitted by electrical signals to the brain through the optic nerve.

In the early stage of RP, mainly rod cells are damaged, resulting in blindness in which the visual acuity diminishes in the dark, the peripheral vision is narrowed, and when it progresses further, conical cells are damaged and it becomes difficult to distinguish colors or objects. The characteristic symptoms are the darkening of the night vision at the early stage of the illness and the gradual disappearance of the peripheral vision. Decreases in central vision are rarely seen at the beginning, but progress to the second half of the disease.

The cause of retinitis pigmentosa is not clear yet, and some environmental factors such as ultraviolet light or virus infection may be the cause, but it is thought to be due to gene abnormality. Recently, there have been reports that inflammatory reaction is an important factor. However, there are still many unknowns about the precise mechanism and etiology. Many patients are blind due to lack of effective treatment. At present, there is no fundamental treatment for RP, and gene therapy, retinal grafting, and drug treatment are performed to slow progress and deterioration and to reduce discomfort in daily life.

Korean Patent No. 10-1449469

In one aspect, the present invention aims to provide a pharmaceutical composition for the prevention or treatment of retinal diseases, which comprises an extract obtained from soybean, which is a soybean plant, as an active ingredient.

In another aspect, the present invention aims to provide a food composition for preventing or ameliorating a retinal disease, which comprises an extract obtained from soybean, which is a soybean plant, as an active ingredient.

In one aspect, the art disclosed herein provides a pharmaceutical composition for the prevention or treatment of retinal diseases, which comprises an extract of soybean curd as an active ingredient.

In another aspect, the technique disclosed in the present specification provides a food composition for preventing or ameliorating a retinal disease, wherein the extract contains a dry bean extract as an active ingredient.

According to one exemplary embodiment, the farina bean extract may be extracted with at least one solvent selected from the group consisting of water, C ₁ to C ₄ lower alcohols, and combinations thereof.

According to one exemplary embodiment, the farina bean extract may be extracted with an organic solvent.

According to one exemplary embodiment, the organic solvent is selected from the group consisting of lower alcohols having 1 to 4 carbon atoms (for example, methanol, ethanol, butanol, etc.), ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, , N, N-dimethylformamide (DMF), methylene chloride, dimethyl sulfoxide (DMSO), glycerin, butylene glycol, propylene glycol, dipropylene glycol, methylene chloride, diethyl ether and mixtures thereof Lt; / RTI >

According to one exemplary embodiment, the farina bean extract may comprise from 0.1 to 50% by weight, based on the total weight of the composition.

According to one exemplary embodiment, the farina bean extract may be one that inhibits photoreceptor cell death of the retina.

According to one illustrative embodiment, the farina bean extract may be one that inhibits neurocytephogenesis that is overexpressed by retinal degeneration.

According to one exemplary embodiment, the retinal disease may be a retinal disease due to retinal degeneration.

According to one exemplary embodiment, the retinal disease may be at least one selected from the group consisting of retinal pigmentary degeneration, macular degeneration, diabetic retinopathy, and retinal detachment.

In one aspect, the technique disclosed in this specification has an effect of providing a pharmaceutical composition for preventing or treating a retinal disease, which comprises an extract obtained from a soybean plant, a snowy bean, as an active ingredient.

In another aspect, the technique disclosed in this specification has an effect of providing a food composition for preventing or ameliorating a retinal disease, which comprises an extract obtained from a leguminous plant, which is a soybean plant, as an active ingredient.

FIG. 1 shows a photograph of a retinal defect photographed in real time using optical coherence tomography (OCT). Specifically, retinal degeneration was induced by using MNU in C57BL / 6 rats, and then the extracts were administered orally for 1 to 4 weeks. In retinal degeneration induced retinal layer thickness, retinal degeneration was inhibited by retinal degeneration in the group treated with oral extract of soybean extract.
FIG. 2 is a photograph showing the effect of the extract of soybean husk on the MNU-induced retinal degenerative animal model by Western blot analysis. Specifically, the extract of bean curd was orally administered for 1 week to 4 weeks after induction of retinal degeneration. In the retinal degeneration - induced animal model, the extracts of the whitish eyes inhibited the cell death of the retinal photoreceptors and inhibited the overexpression of neuroblastoma.

Hereinafter, the present invention will be described in detail.

As used herein, the term "leguminosae" refers to a plant that is native to all parts of Korea, and its stem and leaves are brown. Yellow flowers bloom in July, and black, round fruits of 5 ~ 7 mm in diameter are harvested in the oval pods.

According to the old document "Pruning Gongmok", the bean curd is "warm, tasty, and poisonous." It is better to use a light bean curd and small bean curd as a medicine to control the kidney disease. It is known that it inhibits the fever, activates blood circulation and releases poison. It was used to prevent neuralgia, kidney disease and senile dementia. It is known that the content of isoflavone in soybean is higher than that of yellow soybean, and that cyanidin-3-glucoside among glycitein and anthocyanin components, which are excellent antioxidative effect on seed coat, is abundant and effective for prevention and treatment of cerebrovascular and heart diseases.

According to one illustrative embodiment, the rat is bean is Rhynchosia can be nulubilis . Wheat beans may be cultivated, harvested, or marketed without limitation.

As used herein, the extract means to include all of the crude extract, fractions of the crude extract. In the case of the fractionated extract, fractions obtained by suspending the crude extract in a specific solvent and mixing and leaving with a solvent having a different polarity, and fractions obtained by fractionating the crude extract with a sequential solvent. Concretely, wheat husks are mixed with water, a lower alcohol having 1 to 4 carbon atoms (for example, methanol, ethanol, butanol, etc.), ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N At least one solvent selected from the group consisting of dimethylformamide (DMF), methylene chloride, dimethylsulfoxide (DMSO), glycerin, butylene glycol, propylene glycol, dipropylene glycol, methylene chloride, diethyl ether, , And fractions obtained by fractionating the crude extract. The term " crude extract " At this time, the fractions can be fractionated using the solvents listed above.

Extracts can be prepared by taking into consideration the degree of extraction and the degree of preservation of the active substance, such as hot water extraction, immersion extraction, cold extraction, reflux cooling, ultrasonic extraction, supercritical extraction, An extraction method using an adsorbent resin including XAD and HP-20, or an arbitrary method such as fermentation using a microorganism or natural fermentation can be applied. The number of times of extraction may be 1 to 5 times, and it is preferable to repeat extraction three times, but it is not limited thereto. In addition, after the extraction, a method such as concentration or freeze-drying may be additionally performed.

According to an exemplary embodiment, it is possible to produce a soybean extract by a decompression method using carbon dioxide or a supercritical fluid extraction method at a high temperature. In general, a supercritical fluid is a liquid and a liquid Gas properties and chemically similar polarity to non-polar solvents. Due to these properties, supercritical fluids are being used to extract lipophilic substances. Carbon dioxide is a supercritical fluid with both liquid and gaseous nature, with the operation of supercritical fluid equipment reaching its critical pressure and temperature, resulting in increased solubility in fat-soluble solutes. When supercritical carbon dioxide passes through an extraction vessel containing a certain amount of sample, the lipophilic substance contained in the sample is extracted into supercritical carbon dioxide. When the supernatant carbon dioxide containing a small amount of cosolvent is passed through the sample remaining in the extraction vessel after extracting the lipid-soluble substance, it may be possible to extract components that were not extracted only by pure supercritical carbon dioxide. Such a cosolvent may contain chloroform, ethanol, Methanol, water, ethyl acetate, hexane, and diethyl ether may be used. Most of the extracted samples contain carbon dioxide. Carbon dioxide is volatilized into air at room temperature, and the co-solvent can be removed by decompression evaporator.

According to an exemplary embodiment, it is possible to produce a dry bean extract by ultrasonic extraction using energy generated by ultrasonic vibration. Ultrasonic waves can destroy the insoluble matter contained in the sample in the water-soluble solvent. Since the kinetic energy of the reactant particles located in the periphery is increased due to the high local temperature generated at this time, sufficient energy required for the reaction is obtained. , The high pressure is induced to increase the mixing efficiency of the substance contained in the sample and the solvent, thereby increasing the extraction efficiency.

According to one exemplary embodiment, it is possible to produce a crude soybean extract through a fermentation process. The ground bean is finely crushed to a size of about 100 to 500 mesh, and then a conventional microbial culture liquid is added at 1 to 50 g / L, and microorganisms such as yeast or lactic acid bacteria are added in an amount of 10,000 to 100,000 cfu / L. The culture is carried out at a temperature of 30 to 37 DEG C in a conventional microorganism culture condition and a pH of 5 to 7 is aerobically or anaerobically cultured for about 5 to 10 days after which the extract can be obtained through aging and filtration.

According to an exemplary embodiment, the method for producing the dry bean soybean extract is as follows but is not limited thereto.

1) Extracting dried beans (Rhynchosia Nulubilis) with an extraction solvent;

2) filtering the extract of step 1);

3) preparing an extract by concentrating the filtered extract of step 2) under reduced pressure; And

4) Extracting the extract of step 3) with an organic solvent to prepare fractions.

In one aspect, the extraction solvent in step 1) may be at least one solvent selected from the group consisting of water, a lower alcohol having 1 to 4 carbon atoms, and a mixture thereof, specifically, methanol or ethanol aqueous solution. The amount of the extraction solvent is preferably 1 to 20 times, more preferably 10 times as much as the weight of the soybean. But is not limited thereto.

In another aspect, in the step 1), the extraction method is warmed and may be subjected to reflux extraction, extraction at room temperature, or ultrasonic extraction. The temperature for extraction may be 10 to 100 ° C, specifically 15 to 25 ° C, and the extraction time may be 1 to 7 days, specifically 3 to 7 days, but is not limited thereto.

In another aspect, in the step 3), a vacuum rotary evaporator can be used for the vacuum concentration, and a concentrated liquid phase in which the extraction solvent is removed by hot air drying, vacuum drying, vacuum drying, boiling, spray drying, An extract or a solid form of the extract can be prepared.

In another aspect, in step 4), the organic solvent may be n-hexane, methylene chloride, ethyl acetate or n-butanol. The fractions were prepared by suspending the soybean extract in water and then extracting the fraction of normal-hexane, methylene chloride, ethyl acetate, and n-butanol obtained by sequential fractionation with normal-hexane, methylene chloride, ethyl acetate, n-butanol and water, Fraction or water fraction, and methylene chloride fraction is more preferable, but not limited thereto. The fraction can be obtained by repeating the fractionation process 1 to 5 times, specifically three times, from the soybean extract of the rat, and the fraction can be concentrated under reduced pressure.

According to one exemplary embodiment, the above-mentioned farina bean extract may include at least one of the soybean itself, the extract thereof, the diluted or concentrated solution of the extract, the dried product obtained by drying the extract, and the adjusted product or purified product thereof .

According to one exemplary embodiment, the farina bean extract may comprise from 0.1 to 50% by weight, specifically from 1 to 30% by weight, more specifically from 5 to 25% by weight, based on the total weight of the composition.

According to one exemplary embodiment, the farina bean extract may be one that inhibits photoreceptor cell death of the retina. The soybean extract of the present invention is effective for preventing, ameliorating or treating retinitis pigmentosa due to retinal nerve cell degeneration by protecting photoreceptor cells of the retina.

According to one exemplary embodiment, the retinal disease may be at least one selected from the group consisting of retinal pigmentary degeneration, macular degeneration, diabetic retinopathy, and retinal detachment. The macular degeneration may be senile AMD.

The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of medicaments.

The composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., oral preparations, suppositories and sterilized injection solutions according to a conventional method have.

Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, (sucrose), lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the desired method, and the dose may be appropriately determined depending on the condition of the patient, The range varies depending on diet, excretion rate, severity of disease, drug type, administration time, administration method, administration route and administration period. The daily dose is 0.0001 mg / kg to 500 mg / kg, preferably 0.001 mg / kg to 100 mg / kg, when the extract, fraction or compound according to the present invention is lyophilized, It may be administered once to several times in divided doses.

There is no particular limitation on the type of foods containing the extract of the bean curd according to the present invention. Examples of the foods to which the above substances can be added include dairy products including dairy products such as drinks, meat, sausage, bread, biscuits, rice cakes, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, Beverages, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

Wheat germ extract of the present invention, its fractions or the compounds isolated therefrom can be added directly to food or used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its use purpose (for prevention or improvement). Generally, the amount of the extract in the health functional food may be 0.1 to 90 parts by weight based on the total weight of the food. However, in the case of long-term consumption intended for health or hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

The health functional beverage composition of the present invention has no particular limitation on the other ingredients other than the above-mentioned extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition to the above, the pea extract, its fractions or the compounds isolated therefrom of the present invention can be used as flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents, ), Pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. In addition, the peanut extract of the present invention, its fractions or the compounds isolated therefrom may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the proportion of such additives is not so important, it is common that the wheeze of the present invention is selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the soybean extract or its fractions.

N -methyl- N -nitrosourea (MNU) is an alkyl (alkylating) a compound as nitrogen compounds present in widespread daily environment, it leads to retinal degeneration in a variety of animals. In retinal degenerative animal models of mice, MNU causes photoreceptor apoptosis, which is known to be proportional to dose and time. Immune cell infiltration and proliferation of Muller cells occur after removal of cell debris after MNU-induced retinal damage. MNU, also known as a carcinogen, is a potent mutagen that causes direct alkylation without metabolic activation of the p-450 system.

Since MNU is known to cause retinal degeneration in various animal experiments, MNU is mainly used in experiments for studying retinal pigment degeneration in the ophthalmic field. MNU is toxic to photoreceptor cells and selectively induces apoptosis of photoreceptors leading to retinal degeneration. This toxicity of MNU inhibits DNA adduct formation in the photoreceptor nucleus and upregulation of Bax protein ) And down-regulation of the Bcl-2 protein and activation of the caspase family. The toxicity of MNU to photoreceptors is known to increase in proportion to time and dose.

Thus, the protective effect of retinal degeneration of the farina bean extract disclosed in this specification was confirmed using MNU.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not construed as being limited by these embodiments.

Examples.

To 3 kg of pulverized bean ( Rhynchosia nulubilis ) powder, 2 L of ethanol, specifically ethanol concentration of 70%, was added and sonicated for 4 hours. The extract was filtered. The extract was filtered, and the remaining residue was further subjected to ultrasonic extraction with 15 L of ethanol, specifically a 70% ethanol solvent for 4 hours, to obtain 45 L of the total extract. 45 L of the extract was concentrated under reduced pressure at 35 DEG C to obtain 150 g of a crude soybean ethanol extract.

Experimental example.

It was carried out the same experiment as it targets the retinal degeneration in the rat induced by N -Methyl- N -nitrosourea (MNU) to determine the efficacy of the retinal degeneration in jwinunyi bean extract.

Specifically, male C57BL / 6 mice (Central laboratory animal, Central Lab. Animal Inc.) at 6 weeks of age and 18 to 20 g were used in the experiment as six mice per group. One hour before the induction of retinal degeneration with MNU, the extract of Eugenia officinalis (EERN) obtained in the above example was dissolved in water and orally administered at a dose of 50 mg / Kg. Then MNU dissolved in 0.01 M PBS was intraperitoneally injected at a dose of 50 mg / kg. The control (control) was injected with 0.01 M PBS at the same dose. On the other hand, mice were sacrificed at 1 week and 4th week after MNU injection.

Optical coherence tomography (OCT) was used to observe the effect of soybean extract on the real-time in the MNU-induced retinal degenerative animal model. After the mice were anesthetized, the iris was expanded by instillation of the shadong agent, the anesthetized mouse was fixed on the stand, and retinal tomography was taken using optical coherence tomography.

As a result, as shown in Fig. 1, the thickness of the retina was slightly decreased after 1 week of MNU injection compared with the control (control). After 4 weeks, the retinal layer was disordered and the outer layer was destroyed in the MNU injected group. However, it was confirmed that MNU - induced decrease of retinal thickness was inhibited in the group of mice administered with soybean extract and that retina layer was maintained by protecting the retina. In other words, it was found that the extract of bean curd soybean inhibits the disorder of retinal layer thickness and layer arrangement which is reduced by retinal degeneration.

In addition, Western blotting assay was performed on retinal tissues in order to confirm the neurocyte activity and the photoreceptor cell activity of the extract of soybean curd in the MNU-induced retinal degenerative animal model. After the mice were sacrificed, proteins were extracted from the tissues, and the assays were performed by attaching antigens of proteins (GFAP, glial fibrillary acidic protein) and photoreceptor cell-related proteins (Rhodopsin).

As a result, as shown in Fig. 2, the expression of photoreceptor cells in the retina was decreased and the expression of neurocyte was increased compared to the control group 1 week after MNU injection. After 4 weeks of MNU injection, photoreceptor protein expression completely disappeared and neuroblastoma expression increased rapidly. However, when the extracts of rice husks were treated with soybean extract, it inhibited the expression of glial fibrillary acidic protein (GFAP) and increased the expression of the photoreceptor cell protein (Rhodopsin). That is, the present invention discloses that the extract of bean curd bean extract has a protective effect against retinal degeneration by inhibiting retinal photoreceptor cell death and inhibiting the expression of a neurotrophic factor activated when retinal degeneration occurs.

Therefore, it has been confirmed that the pea extract of the present invention disclosed in the present invention is effective in preventing, ameliorating, or treating retinal diseases associated with retinal cell degeneration by protecting the retinas, in particular retinal photoreceptor cells, from degradation.

Formulation examples of the composition according to one aspect of the present invention are described below, but may be applied to various other preparations, which should not be construed as limiting the present invention.

[Formulation Example 1] Preparation of eye drop gel

Peony Extract 5 mg

Carbopol 934 20 mg

Triethanolamine Amount

Paraoxine benzoic acid methyl 2 mg

Sterile purified water ad. 1 g

To the sterile purified water was added paraoxine benzoic acid methylate, heated to dissolve, cooled, and the bean extract dissolved. Carbopol 934 mg was added thereto, followed by mixing and dispersing in a high-speed stirrer, followed by standing to remove air. To this, triethanolamine was added dropwise while being carefully stirred so as not to allow air to enter.

[Formulation Example 2] Preparation of eye drops

5 grams of pea extract

0.1 g of benzalkonium chloride

5 g of sodium chloride

Boric acid 6.2 g

Tylocapol 1.0 g

Dilute hydrochloric acid qs

1000 ml of sterile purified water

Sodium chloride and boric acid were added to and dissolved in the soybean extract of the whiting eye, and then benzalkonium chloride and thylocapol dissolved in a small amount of sterilized purified water were added and stirred. The pH was adjusted by adding dilute hydrochloric acid. Sterilization was performed using a 0.45 microfilter.

[Formulation Example 3] Preparation of eye dropping ointment agent

Peony Extract 5 mg

Sterilized purified water 10 mg

2 mg of p-hydroxybenzoic acid methyl

100 mg of anhydrous lanolin

White petrolatum 1 g

The amniotic membrane extract and the p-hydroxybenzoic acid methylate were taken in sterilized glass bowl, and the husks were melted with soybean extract and mixed with anhydrous lanolin until they became homogeneous.

[Formulation Example 4] Soft capsule

Soft bean extract was prepared by mixing 330 mg of soybean extract, 50 mg of red ginseng extract, 2 mg of palm oil, 8 mg of palm kernel oil, 4 mg of yellow pearls and 6 mg of lecithin and 400 mg per capsule according to a conventional method.

[Formulation Example 5] Tablets

Mixed 150 mg of soybean extract, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch and 4 mg of magnesium stearate, and 40 mg of 30% ethanol was added to form granules. The granules were then dried at 60 ° C., Respectively.

[Formulation Example 6] Granules

The granules were prepared by mixing 150 mg of soybean extract, 100 mg of glucose, 50 mg of red ginseng extract and 600 mg of starch and 100 mg of 30% ethanol, and dried at 60 ° C. to form granules. The final weight of the contents was 1 g.

[Formulation Example 7] Drug agent

150 mg of soybean extract, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid and 187.8 g of purified water were mixed and filled into bottles. The final volume of the contents was adjusted to 200 ml.

[Formulation Example 8] Preparation of health food

Peanut extract: 1000 mg

Vitamin mixture

Vitamin A Acetate ............... 70 ㎍

Vitamin E ........................ 1.0 mg

Vitamin B1 ........................ 0.13 mg

Vitamin B2 ....................... 0.15 mg

Vitamin B6 ........................ 0.5 mg

Vitamin B12 ....................... 0.2 g

Vitamin C .......................... 10 mg

Biotin ............................ 10 ㎍

Nicotinic acid amide ... 1.7 mg

Folic acid ............................... 50 ㎍

Calcium pantothenate ...................... 0.5 mg

Mineral mixture

Ferrous sulfate ....................... 1.75 mg

Zinc oxide ........................ 0.82 mg

Magnesium carbonate .................... 25.3 mg

Potassium phosphate monohydrate 15 mg

Secondary calcium phosphate .................... 55 mg

Potassium citrate ......................... 90 mg

Calcium carbonate ........................... 100 mg

Magnesium chloride ....................... 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

[Formulation Example 9] Preparation of health drink

Peanut extract of soybean .............. 1000 mg

Citric acid ....................... 1000 mg

Oligosaccharides ...................... 100 g

Plum concentrate ...................... 2 g

Taurine .......................... 1 g

Purified water was added to the entire mixture. 900 ml

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, &Lt; / RTI >

Although the above-mentioned composition ratio is a mixed composition of a comparatively suitable component as a preferred embodiment, the compounding ratio may be arbitrarily varied depending on the local or national preference such as demand stratum, demand country, use purpose, and the like. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

Having described specific portions of the present invention in detail, it will be apparent to those skilled in the art that this specific description is only a preferred embodiment and that the scope of the present invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims

A pharmaceutical composition for the prevention or treatment of retinal diseases, comprising extracts of soybean as an active ingredient.

A food composition for preventing or ameliorating a retinal disease, which comprises an extract of soybean as an active ingredient.

3. The method according to claim 1 or 2,
Wherein the farina bean extract is extracted with at least one solvent selected from the group consisting of water, C ₁ to C ₄ lower alcohols, and combinations thereof.

3. The method according to claim 1 or 2,
Wherein the crude soybean extract is included in an amount of 0.1 to 50% by weight based on the total weight of the composition.

3. The method according to claim 1 or 2,
Wherein the dry extract of soybean curd suppresses the photoreceptor cell death of the retina.

3. The method according to claim 1 or 2,
The composition of claim 1, wherein the soybean extract inhibits neuroblastogenesis overexpressed by retinal degeneration.

3. The method according to claim 1 or 2,
The retinal disease is a retinal disease caused by retinal degeneration.

3. The method according to claim 1 or 2,
Wherein the retinal disease is at least one selected from the group consisting of retinal pigmentary degeneration, macular degeneration, diabetic retinopathy, and retinal detachment.